Balancing volume resuscitation and ascites management in cirrhosis

Current Opinion in Anaesthesiology

Volumn 23, Issue 2, 2010, Pages 151-158

  Polli, Federico ^a   Gattinoni, Luciano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Ascites; Fluid therapy; Haemodynamics; Liver cirrhosis; Serum albumin

Indexed keywords

ALBUMIN; ANGIOTENSIN II; MIDODRINE; NORADRENALIN; OCTREOTIDE; PLACEBO; SODIUM CHLORIDE; TERLIPRESSIN; VASOPRESSIN;

ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FLUID RESUSCITATION; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; HYPOVOLEMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; THERAPY RESISTANCE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT RESPONSE;

ALBUMINS; BODY FLUIDS; FLUID THERAPY; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; NEUROTRANSMITTER AGENTS; RESUSCITATION;

EID: 77952198839     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833724da     Document Type: Review

References (114)

1. Volk ML, Marrero JA. Advances in critical care hepatology. Minerva Anestesiol 2006;72:269-281.
2. du Cheyron D, Bouchet B, Parienti JJ, et al. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005;31:1693-1699. (Pubitemid 41677246)
3. Arabi Y, Ahmed QA, Haddad S, et al. Outcome predictors of cirrhosis patients admitted to the intensive care unit. Eur J Gastroenterol Hepatol 2004;16:333-339.
4. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128.
5. Levy M. Pathogenesis of sodium retention in early cirrhosis of the liver: evidence for vascular overfilling. Semin Liver Dis 1994;14:4-13.
6. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
7. Henriksen JH, Bendtsen F, Sorensen TI, et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989;97:1506-1513.
8. Vanheule E, Geerts AM, Van Huysse J, et al. An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. Int J Exp Pathol 2008;89:419-432.
9. Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009;50:604-620.
10. Angus PW. Role of endothelin in systemic and portal resistance in cirrhosis. Gut 2006;55:1230-1232.
11. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, et al. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007;47:220-227.
12. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-491.
13. Xu J, Cao H, Liu H, Wu ZY. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension. Hepatobiliary Pancreat Dis Int 2008;7:503-508.
14. Sitzmann JV, Campbell K, Wu Y, St Clair C. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension. Surgery 1994;115:290-294.
15. Bolognesi M, Sacerdoti D, Piva A, et al. Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats. J Pharmacol Exp Ther 2007;321:187-194.
16. Van Landeghem L, Laleman W, Vander Elst I, et al. Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int 2009;29:650-660.
17. Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB (1) and VR (1) receptors. Br J Pharmacol 2006;149:898-908.
18. Iwao T, Oho K, Sakai T, et al. Splanchnic and extrasplanchnic arterial hemodynamics in patients with cirrhosis. J Hepatol 1997;27:817-823.
19. Moller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumesin cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003;284: G970-G979.
20. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990;113:155-159.
21. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290.
22. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994;20:1356-1358.
23. Gentilini P, Romanelli RG, Laffi G, et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 1999;30:632-638.
24. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med 2008;29:119-129.
25. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991;13:689-694.
26. Moreau R, Hadengue A, Soupison T, et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 1990;12:7-12.
27. Karatapanis S, McCormick PA, Kakad S, et al. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology 1994;20:1516-1521.
28. Heller J, Schepke M, Gehnen N, et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999;116:387-393.
29. MacGilchrist AJ, Reid JL. Impairment of autonomic reflexes in cirrhosis. Am J Gastroenterol 1990;85:288-292.
30. Fleckenstein JF, Frank S, Thuluvath PJ. Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. Hepatology 1996;23:471-475.
31. Dumcke CW, Moller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand J Clin Lab Invest 2008;68:437-447.
32. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
33. Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and nonalcoholic cirrhosis. J Hepatol 1995;22:326-332.
34. Moller S, Henriksen JH, Bendtsen F. Ascites: pathogenesis and therapeutic principles. Scand J Gastroenterol 2009;44:902-911.
35. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
36. Zambruni A, Trevisani F, Di Micoli A, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008;48:415-421.
37. Kiszka-Kanowitz M, Henriksen JH, Moller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gammacamera technique. J Hepatol 2001;35:605-612.
38. Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics. Gut 2006;55:380-387.
39. Brinch K, Moller S, Bendtsen F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003;39:24-31.
40. Hori T, Yagi S, Iida T, et al. Stability of cirrhotic systemic hemodynamics ensures sufficient splanchnic blood flow after living-donor liver transplantation in adult recipients with liver cirrhosis. World J Gastroenterol 2007;13:5918-5925.
41. Hori T, Yagi S, Iida T, et al. Optimal systemic hemodynamic stability for successful clinical outcomes after adult living-donor liver transplantation: prospective observational study. J Gastroenterol Hepatol 2008;23(7 Pt 2): e170-e178.
42. Camps J, Sola J, Arroyo V, et al. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 1987;93:498-505.
43. Esteva-Font C, Baccaro ME, Fernandez-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology 2006;44:1555-1563.
44. Vercueil A, Grocott MP, Mythen MG. Physiology, pharmacology, and rationale for colloid administration for the maintenance of effective hemodynamic stability in critically ill patients. Transfus Med Rev 2005;19:93-109.
45. Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:191 7-1925.
46. Andreu V, Perello A, Moitinho E, et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol 2002;36:356-361.
47. Hadengue A, Moreau R, Gaudin C, et al. Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology 1992;15:809-815.
48. Henriksen JH, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999;31:712-718.
49. Henriksen JH, Fuglsang S, Bendtsen F, et al. Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. Am J Physiol Gastrointest Liver Physiol 2001;280: G584-G594.
50. Henriksen JH, Moller S, Schifter S, et al. High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems. Gut 2001;49:112-118.
51. Henriksen JH, Gulberg V, Gerbes AL, et al. Increased arterial compliance in cirrhosis is related to decreased arterial C-type natriuretic peptide, but not to atrial natriuretic peptide. Scand J Gastroenterol 2003;38:559-564.
52. Umgelter A, Wagner K, Reindl W, et al. Haemodynamic effects of plasma- • expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study. BMC Gastroenterol 2008;8:39. This study demonstrates the usefulness of goal-directed volumetric assessment of fluid resuscitation in patients with advanced cirrhosis.
53. Umgelter A, Reindl W, Wagner KS, et al. Effects of plasma expansion with • albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 2008;12: R4. This study demonstrates the usefulness of goal-directed volumetric assessment of fluid resuscitation in patients with advanced cirrhosis.
54. Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008;134:172-178.
55. Della RG, Costa MG, Coccia C, et al. Preload and haemodynamic assessment during liver transplantation: a comparison between the pulmonary artery catheter and transpulmonary indicator dilution techniques. Eur J Anaesthesiol 2002;19:868-875.
56. Cochrane Injuries Group. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 1998;317:235-240.
57. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;135:149-164.
58. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg 2003;237:319-334.
59. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004: CD001208.
60. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-2256. (Pubitemid 38669207)
61. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock - 2008. Crit Care Med 2008;36:296-327.
62. Henriksen JH, Siemssen O, Krintel JJ, et al. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol 2001;34:53-60.
63. Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat'tense' ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987;5:102-108.
64. De Gottardi A, Thevenot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009;7:906-909.
65. Runyon BA. Management of adult patients with ascites due to cirrhosis: an • update. Hepatology 2009;49:2087-2107. A comprehensive guideline on the current management of patients with cirrhosis and ascites.
66. Ruiz-del-Arbol L, Monescillo A, Jimenez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-586.
67. Simon DM, McCain JR, Bonkovsky HL, et al. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology 1987;7:423-429.
68. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995;22:753-758.
69. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1502.
70. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1010.
71. Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997;17:163-173.
72. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146-151.
73. Garcia-Compean D, Zacarias VJ, Bahena CH, et al. Total therapeutic paracentesis (TTP) with and without intravenous albumininthe treatmentofcirrhotic tense ascites: a randomized controlled trial. Liver 1993;13:233-238.
74. Laffi G, Gentilini P, Romanelli RG, La Villa G. Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig Liver Dis 2003;35:660-663.
75. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009;23:183-191.
76. Rothschild MA, Oratz M, Evans C, Schreiber SS. Alterations in albumin metabolism after serum and albumin infusions. J Clin Invest 1964;43:1874-1880.
77. Pietrangelo A, Panduro A, Chowdhury JR, Shafritz DA. Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat. J Clin Invest 1992;89:1755-1760.
78. Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990;99:1736-1744.
79. Garcia-Compean D, Blanc P, Larrey D, et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002;1:29-35.
80. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-1153.
81. Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006;26:46-54.
82. Terg R, Miguez CD, Castro L, et al. Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis. J Hepatol 1996;25:329-333.
83. Wong CL, Holroyd-Leduc J, Thorpe KE, Straus SE. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA 2008;299:1166-1178.
84. Christidis C, Mal F, Ramos J, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001;35:726-732.
85. Lata J, Marecek Z, Fejfar T, et al. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites: a randomized multicentric study. Hepatogastroenterology 2007;54:1930-1933.
86. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albuminonarterial blood volumeinpatients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90-94.
87. Singh V, Kumar R, Nain CK, et al. Terlipressin versus albumin in paracentesisinduced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006;21(1 Pt 2):303-307.
88. Appenrodt B, Wolf A, Grunhage F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008;28:1019-1025.
89. Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin inparacentesisinduced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006;260:62-68.
90. Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008;103:1399-1405.
91. Singh RG. Terlipressin and arterial blood volume after paracentesis for tense ascites in cirrhosis. Gut 2002;51:755.
92. Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol 1997;92:394-399.
93. Cardenas A, Gines P, Runyon BA. Is albumin infusion necessary after large • volume paracentesis? Liver Int 2009;29:636-640. An interesting pro-con debate on the opportunity of using albumin for the prevention of paracentesis-induced circulatory dysfunction.
94. Koulaouzidis A, Bhat S, Saeed AA. Spontaneous bacterial peritonitis. World J Gastroenterol 2009;15:1042-1049.
95. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501.
96. Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627-634.
97. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
98. Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597-599.
99. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome • in patients with cirrhosis. J Hepatol 2008;48(Suppl 1): S93-S103. An up-to-date review of the therapeutic options for the hepatorenal syndrome.
100. Platt JF, Ellis JH, Rubin JM, et al. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994;20:362-369.
101. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447.
102. Carl DE, Sanyal A. The management of hepatorenal syndrome. Minerva Gastroenterol Dietol 2009;55:207-226.
103. Koppel MH, Coburn JW, Mims MM, et al. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-1371.
104. Piscaglia F, Zironi G, Gaiani S, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999;30:58-64.
105. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318. (Pubitemid 47300435)
106. Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003;50:1753-1755.
107. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-295.
108. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-380.
109. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
110. Esrailian E, Pantangco ER, Kyulo NL, et al. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-748.
111. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
112. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935-944.
113. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, doubleblind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.
114. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36(4 Pt 1):941-948.